Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients. Primary urothelial cancer has variable ...

In a phase 3 trial, more deaths due to adverse events were reported in the Trodelvy arm compared with the chemotherapy arm. Gilead has made the decision to withdraw the accelerated approval of ...

Bavencio maintenance therapy is effective and generally well-tolerated in urothelial cancer patients, with minimal side effects for most. Patients on Bavencio lived an average of 17 months, with ...

Disparities in Endometrial Cancer Mortality: Will Increasing Use of Targeted Therapies Widen the Gap? Urothelial carcinoma (UC) is the most common malignancy of the urinary tract, with urothelial ...

Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed Primary ...

Circulating tumor DNA (ctDNA) is an emerging technology that is rapidly transforming the management of patients with cancer -- not only in hematologic malignancies, but increasingly also in solid ...

Urothelial cancer (UC) is the most common histology seen in bladder tumors. The 2022 WHO classification of urinary tract tumors includes a list of less common subtypes (formerly known as variants) for ...

For patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) (EV+P) continued to ...

Urothelial carcinoma accounts for the vast majority of bladder cancers and presents along a continuum from non-muscle-invasive lesions to muscle-invasive and metastatic disease. Non-muscle-invasive ...